The race to bring new medicines to patients just got a $7.0M boost for Double Blind Bio, which announced a seed funding round to accelerate its AI-driven approach to clinical trials. The company is building intelligent agents designed to automate complex workflows for sponsors and research sites.
Double Blind Bio's technology tackles everything from initial site selection and feasibility studies through to study startup and execution. By streamlining these critical stages, the startup aims to move trials faster and ensure medicines reach patients sooner.
















